Claims
- 1. A compound having the formula (I):
- 2. The compound of claim 1 wherein
- 3. The compound of claim 1 wherein Q is —N(R)—.
- 4. The compound of claim 1 wherein R3 is hydrogen or ═O.
- 5. The compound of claim 1 wherein
- 6. A compound having the formula (II):
- 7. The compound of claim 6, wherein R4 is hydrogen.
- 8. The compound of claim 6, wherein R″ is hydrogen.
- 9. The compound of claim 8, wherein R2 is (C1-C4)alkyl or aryl.
- 10. The compound of claim 9, wherein R1 is independently selected from the group consisting of halogen, (C1-C4)alkyl, fluoro(C1-C4)alkyl, —OR5, fluoro(C1-C4)alkoxy, —CO2R5, —S(O)mNR5R6, —S(O)mR5 and —CN.
- 11. The compound of claim 10, wherein R1 is halogen or fluoro(C1-C4)alkyl.
- 12. The compound of claim 10, wherein n is 0 or 1.
- 13. The compound of claim 12, wherein L1 is (C1-C4)alkylene.
- 14. The compound of claim 13, having the formula (III):
- 15. The compound of claim 13, wherein p is 1, 2 or 3.
- 16. The compound of claim 15, wherein L2 is a bond.
- 17. The compound of claim 16, wherein Z is —CO2R15 or —CO2NR15R16.
- 18. The compound of claim 15, wherein X and Y are combined to form a 3-, 4-, 5-, 6- or 7-membered ring containing from 0 to 2 heteroatoms selected from the group consisting of O, N and S.
- 19. The compound of claim 18, wherein X and Y are combined to form a 5- or 6-membered ring containing from 0 to 2 heteroatoms selected from the group consisting of O, N and S.
- 20. The compound of claim 19, wherein X and Y are combined to form a 5- or 6-membered ring containing 0 heteroatoms, 1 nitrogen atom or 1 oxygen atom.
- 21. The compound of claim 6, having the formula (IV):
- 22. The compound of claim 21, wherein p is 1, 2 or 3.
- 23. The compound of claim 22, wherein p is 2.
- 24. The compound of claim 23, wherein Y is —CO2H.
- 25. The compound of claim 23, wherein X and Y are combined to form a 3-, 4-, 5-, 6- or 7-membered ring containing from 0 to 2 heteroatoms selected from the group consisting of O, N and S.
- 26. The compound of claim 23, wherein X and Y are combined to form a 5- or 6-membered ring containing from 0 to 2 heteroatoms selected from the group consisting of O, N and S.
- 27. The compound of claim 23, wherein X and Y are combined to form a 5- or 6-membered ring containing 0 heteroatoms, 1 nitrogen atom or 1 oxygen atom.
- 28. The compound of claim 23, wherein X and Y are combined to form a 5- or 6-membered ring containing 0 heteroatoms, 1 nitrogen atom or 1 oxygen atom and Y is —CO2H.
- 29. The compound of claim 23, wherein R2 is methyl.
- 30. The compound of claim 23, wherein R1 is CF3.
- 31. The compound of claim 30, wherein R1 is 9-trifluoromethyl.
- 32. The compound of claim 23, wherein R1 is CF3 and R2 is methyl.
- 33. The compound of claim 23, wherein R1 is CF3, R2 is methyl and Y is —CO2H.
- 34. The compound of claim 33, wherein said compound is selected from the group consisting of the group consisting of:
- 35. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound of any one of claims 1-34.
- 36. A method for treating a condition or disorder is selected from the group consisting of obesity, an eating disorder, an anxiety disorder and a mood disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 or 6.
- 37. The method of claim 36, wherein said compound condition or disorder is selected from the group consisting of obesity, anorexia nervosa, anxiety, panic disorder and obsessive-compulsive disorder and depression.
- 38. The method of claim 36, wherein said compound is administered in combination with an anti-obesity agent, an antidepressant or an anxiolytic agent.
- 39. The method of claim 36, wherein said compound is administered orally.
- 40. The method of claim 36, wherein said compound is administered parenterally.
- 41. The method of claim 36, wherein said compound modulates MCHR.
- 42. A method for modifying eating behavior, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 or 6.
- 43. The method of claim 42, wherein food intake is decreased.
- 44. The method of claim 42, wherein food intake is increased.
- 45. A method for treating a condition or disorder mediated by MCHR, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 or 6.
- 46. The method of claim 45, wherein said condition or disorder is selected from the group consisting of obesity, an eating disorder, an anxiety disorder and a mood disorder.
- 47. The method of claim 46, wherein said eating disorder is anorexia nervosa.
- 48. The method of claim 46, wherein said anxiety disorder is selected from the group consisting of anxiety, panic disorder and obsessive-compulsive disorder.
- 49. The method of claim 46, wherein said mood disorder is depression.
- 50. A method for modulating MCHR, comprising contacting a cell with a compound of claim 1 or 6.
- 51. The method of claim 50, wherein said compound is an MCHR antagonist.
- 52. The method of claim 50, wherein said compound is an MCHR agonist.
Parent Case Info
[0001] This application claims the benefit under 35 U.S.C. § 119 of U.S. provisional application No. 60/424,456, the contents of which are hereby incorporated by reference in their entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60424456 |
Nov 2002 |
US |